EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem

Amirhossein Sahebkar iD, Wael Almahmeed iD, Prashant Kesharwani iD, Tannaz Jamialahmadi iD

Cardiovascular Therapeutics · 2026

DOI: 10.1155/cdr/7328020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Amirhossein Sahebkar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research Center, Pharmaceutical Technology Institute, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, mums.a…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Proprotein Convertase 9, Dyslipidemias. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iran National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel contributor to atrial fibrillation (AF) pathophysiology. Recent studies suggest that elevated PCSK9 levels may promote AF through multiple mechanisms, including platelet activation, oxidative stress, vascular calcification, and structural atrial remodeling. PCSK9 inhibitors such as alirocumab, evolocumab, and newer agents like inclisiran have shown potential in reducing AF incidence and cardiovascular events, particularly in high‐risk populations. However, evidence from randomized controlled trials with AF as a primary clinical endpoint is limited. Further mechanistic and interventional research is warranted to establish optimized therapeutic strategies targeting PCSK9 in AF prevention and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationProprotein Convertase 9DyslipidemiasHumansPCSK9 InhibitorsAnimalsSerine Proteinase InhibitorsOxidative StressRisk FactorsTreatment OutcomeAtrial RemodelingSignal TransductionAnti-Arrhythmia Agents

Stichwörter der Autor:innen

PCSK9PCSK9 inhibitorsarrhythmiaatrial fibrillationcholesterollipoproteinoxidative stressplatelet activationvascular calcification

Substanzen

Proprotein Convertase 9PCSK9 protein, humanPCSK9 InhibitorsSerine Proteinase InhibitorsAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Biotechnology Research Center, Pharmaceutical Technology Institute, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
  • Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India, chitkara.edu.in.
  • Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
  • Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE, clevelandclinicabudhabi.ae.
  • Next-Generation Translational Nanomedicine Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
  • University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India, chandigarhuniversity.ac.in.

ORCID-Profile: Amirhossein Sahebkar, Wael Almahmeed, Prashant Kesharwani, Tannaz Jamialahmadi

Förderung

  • Iran National Science Foundation

Zitieren

APA

Sahebkar, A., Almahmeed, W., Kesharwani, P., & Jamialahmadi, T. (2026). PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/7328020

Vancouver

Sahebkar A, Almahmeed W, Kesharwani P, Jamialahmadi T. PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/7328020

BibTeX
@article{Sahebkar2026,
  author = {Sahebkar, Amirhossein and Almahmeed, Wael and Kesharwani, Prashant and Jamialahmadi, Tannaz},
  title = {PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  doi = {10.1155/cdr/7328020}
}
Kostenlos starten →